Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu dopisy, práce podpořená grantem
PubMed
35702878
PubMed Central
PMC9349555
DOI
10.1002/ajh.26626
Knihovny.cz E-zdroje
- MeSH
- COVID-19 * MeSH
- hematologické nádory * MeSH
- lidé MeSH
- průzkumy a dotazníky MeSH
- SARS-CoV-2 MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- dopisy MeSH
- práce podpořená grantem MeSH
Centro de Investigación del Cáncer IBMCC IBSAL Salamanca Spain
CIBERINFEC Instituto de Salud Carlos 3 Madrid Spain
Deparment of Hematology Hospital Universitario de Cabueñes Gijón Spain
Deparment of Hematology Hospital Universitario Infanta Leonor Madrid Spain
Departament de Medicina Universitat Autònoma de Barcelona Bellaterra Spain
Department of Clinical and Biological Sciences San Luigi Gonzaga Hospital Orbassano Orbassano Italy
Department of Clinical and Biological Sciences University of Turin Turin Italy
Department of Haematology Complejo Hospitalario de Navarra Pamplona Spain
Department of Hematology and Oncology Medical University of Innsbruck Innsbruck Austria
Department of Hematology Centro Hospitalar e Universitário de São João Porto Portugal
Department of Hematology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark
Department of Hematology Hospital Universitario Marqués de Valdecilla Santander Spain
Department of Hematology Radboud University Medical Center Nijmegen The Netherlands
Department of Hematology University Hospital Dubrava Zagreb Croatia
Department of Hematology University Medical Center Groningen Groningen The Netherlands
Department of Infectious Diseases CHU de Strasbourg Strasbourg France
Department of Infectious Diseases Karolinska University Hospital Stockholm Sweden
Department of Internal Medicine Hematology ADRZ Goes Netherlands
Department of Mental Health and Public Medicine Universitry of Campania Naples Italy
Department of Nephrology and Infectious diseases AZ Sint Jan Brugge Oostende AV Brugge Belgium
Department Oncology AZ KLINA Brasschaat Belgium
German Centre for Infection Research Partner Site Bonn Cologne Cologne Germany
Health Research Institute IIS FJD Fundacion Jimenez Diaz University Hospital Madrid Spain
Hemato Oncology Department Hopital Saint Louis Paris France
Hematology and Stem Cell Transplant Unit IRCCS Regina Elena National Cancer Institute Rome Italy
Hematology and Stem Cell Transplant Unit Vito Fazzi Hospital Lecce Italy
Hematology and Stem Cell Transplantation Unit AOUC Policlinico Bari Italy
Hematology Department Hospital Universitario de Salamanca Salamanca Spain
Hematology Unit ASST Spedali Civili Brescia Italy
Hematology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
Hematology Unit Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Hematology Unit Università Cattolica del Sacro Cuore Rome Italy
Infectious Diseas Clinic ASU FC Udine Hospital Udine Italy
Medizinische Klinik 2 Klinikum rechts der Isar TU München Munich Germany
Microbiology and Parasitology Department University Hospital La Paz Madrid Spain
Pamela Youde Nethersole Eastern Hospital Hong Kong Hong Kong SAR
Respiratory Department Northumbria Healthcare Newcastle UK
Service d'Hématologie Centre Hospitalier de Versailles Le Chesnay France
Zobrazit více v PubMed
Pagano L, Salmanton‐Garcia J, Marchesi F, et al. COVID‐19 infection in adult patients with hematological malignancies: a European Hematology Association survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. PubMed PMC
Bruel T, Hadjadj J, Maes P, et al. Serum neutralization of SARS‐CoV‐2 omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med. 2022;28(6):1297‐1302. PubMed
Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS‐CoV‐2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303‐1312. PubMed PMC
Christensen PA, Olsen RJ, Long SW, et al. Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the omicron variant of severe acute respiratory syndrome coronavirus 2 in Houston, Texas. Am J Pathol. 2022;192(4):642‐652. PubMed PMC
Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA‐1273 against SARS‐CoV‐2 omicron and Delta variants. Nat Med. 2022;28(5):1063‐1071. PubMed PMC
Salmanton‐Garcia J, Busca A, Cornely OA, et al. EPICOVIDEHA: a ready to use platform for epidemiological studies in hematological patients with COVID‐19. Hema. 2021;5(7):e612. PubMed PMC
Niemann CU, da Cunha‐Bang C, Helleberg M, Ostrowski SR, Brieghel C. Patients with CLL have lower risk of death from COVID‐19 in the omicron era. Blood. Published online May 19, 2022. doi:10.1182/blood.2022016147 PubMed DOI PMC
Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid‐19 from omicron, delta, and alpha SARS‐CoV‐2 variants in the United States: prospective observational study. BMJ. 2022;376:e069761. PubMed PMC
Ollila TA, Lu S, Masel R, et al. Antibody response to COVID‐19 vaccination in adults with hematologic malignant disease. JAMA Oncol. 2021;7(11):1714‐1716. PubMed PMC
Group RC . Casirivimab and imdevimab in patients admitted to hospital with COVID‐19 (RECOVERY): a randomised, controlled, open‐label, platform trial. Lancet. 2022;399(10325):665‐676. PubMed PMC
